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Cytomegalovirus antibodies among healthy blood donors at 
Lagos University Teaching Hospital
A A Akinbami, A S Akanmu, T A Adeyemo, K O Wright, M O Dada, A O Dosunmu
Human cytomegalovirus (CMV) is a ubiquitous agent that 
commonly infects individuals from diverse geographical 
and socio-economic backgrounds. Although most CMV 
infections are asymptomatic, certain patient groups are at risk 
of developing serious illness and long-term sequelae from 
CMV infection. CMV remains the leading cause of congenital 
viral infection and a significant cause of transfusion-acquired 
infections in the immunocompromised.
Blood transfusion and CMV infection
Tolpin et al.1 provided the first biochemical and molecular 
evidence for transfusion-associated (TA) CMV infection. 
They reported that monocytes latently infected with CMV 
represent the primary vector for TA-CMV, which can be 
largely abrogated by transfusing at-risk patients with either 
seronegative units or blood filtered to remove white blood 
cells.1 About 3% of healthy blood donors are actively infected 
with the virus at the time of donation.2 In the USA, 5.7% of 
healthy blood donors had CMV isolated from peripheral 
blood.3
CMV-specific antibody of the IgM class is a marker of active 
or recent primary infection with the virus. Post-transfusion 
CMV infection correlates positively with the receipt of blood 
from CMV IgM-positive donors.4 A decreased incidence of 
TA-CMV infection was reported when only blood products 
negative for CMV IgM were used.5
Seroprevalence of CMV among blood donors
A World Health Organization (WHO)-sponsored survey 
of complement-fixing antibodies against CMV reported 
frequencies ranging from 40% in highly industrialised areas, 
to 100% in developing countries; Nigerian blood donors from 
Ibadan were 100% seropositive.6
A study of the seroprevalence of CMV among voluntary 
blood donors in India reported that none of the 200 donors 
tested positive for CMV IgM antibody, but 95% were positive 
for CMV IgG antibody.7 Pal et al. in Chandigarh, India, showed 
100% seropositivity for CMV in the population aged >20 years,8 
while Madhavan et al. in Pondicherry showed that 84 - 96% 
of adults had the antibody.9 The high seroprevalence in India 
contrasts with Western literature in which seroprevalence in 
voluntary blood donors ranges from 38% to 75%.10
The American Association of Blood Banks has recommended 
transfusion from donors who are seronegative for CMV, 
or the use of deglycerolised frozen red blood cells (RBCs) 
for transfusion in a seronegative preterm (<1 200 g) child 
born to a mother with negative or unknown immune status 
regarding CMV infection.11 These guidelines have helped to 
eliminate transfusion-induced CMV infection syndrome in 
preterm infants in the West. However, since the vast majority 
of blood donors in developing countries are seropositive 
for CMV, it would be imprudent to screen blood donors 
for CMV as very few seronegative blood units would be 
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Objectives. Cytomegalovirus (CMV) is found worldwide in all 
geographical locations and socio-economic groups and is the 
virus most frequently transmitted to a developing child before 
birth. This study aimed to determine the prevalence and risk 
factors for CMV antibodies among healthy blood donors at 
Lagos University Teaching Hospital (LUTH).
Methods. A cross-sectional study was carried out among 
consecutively recruited replacement blood donors attending 
the blood donor clinic at LUTH. A 5 ml blood sample was 
collected from each consenting participant and serum-assayed 
for CMV IgG/IgM using an enzyme-linked immunosorbent 
assay (ELISA)-based kit.
Results. A total of 122 healthy donors were recruited; 96% of 
the donors were IgG anti-CMV positive while 19.5% were 
IgM anti-CMV positive. Previous history of blood transfusion 
was not significantly related to CMV positivity.
Conclusion. The seroprevalence of CMV appears to be very 
high in this environment among healthy blood donors. Based 
on previous studies that showed a decrease in the incidence 
of CMV disease when blood is screened for CMV (IgM), the 
incidence of the disease can be decreased in Lagos if blood is 
screened for CMV.
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available for transfusion. Other preventive strategies (such 
as leukoreduction filtration, saline-washed RBCs, frozen 
deglycerolised RBCs, etc.) are increasingly recommended to 
minimise transfusion transmission of CMV.12 These methods 
may be more appropriate and cost-effective in developing 
countries for the prevention of CMV transmission through 
infected blood to immunosuppressed individuals. More 
studies are needed to elucidate the transmission of transfusion-
associated CMV before proper guidelines on routine CMV 
screening in blood donors can be formulated.
Methods
A cross-sectional study was done at the blood donor clinic 
of the Lagos University Teaching Hospital, which registers 
an average of 30 replacement donors daily. All consenting 
donors were recruited consecutively between 8 July and 20 
August 2006. Approval was obtained from the institution’s 
research and ethics committee. Participants were asked 
and aided to fill the structured questionnaires, including 
demographic information and history of previous exposure 
to blood transfusion. Inclusion criteria were: age 18 - 60 years, 
weight >50 kg, haemoglobin >12.5 g/dl, and normal blood 
pressure, pulse and temperature. Exclusion criteria were: 
history of chronic illness (e.g. hypertension, diabetes, asthma), 
commercial sex workers and intravenous drug users.
Collection of samples
A blood sample of 5 ml was collected into a sterile un-
anticoagulated bottle, which was centrifuged, serum-separated 
into a sterile bottle and stored at –20oC. Sera were tested for 
IgG and IgM CMV by the enzyme-linked immunosorbent 
assay (ELISA) test. The CMV-specific IgG/IgM antibodies were 
studied by the commercial Dia.Pro Diagnostic Bioprobes CMV 
IgG/IgM ELISA Kit (Italy), according to the manufacturer’s 
instructions. All specimens were analysed using the enzyme 
immunoassay test. The cut-off of IgG was set at 0.5 WHO 
IU/ml (Calibrator 2) by the kit’s manufacturer. Samples with 
a concentration >0.5 WHO IU/ml were considered positive 
for CMV IgG, with samples with concentration below the cut-
off as negative results. IgM test results were interpreted as a 
ratio of the sample optical density (OD) of 450 nm and the 
sample rate/cut-off value (S/Co) as follows: <1.0=negative; 
1.0 - 1.2=equivocal; and >1.2=positive. The controls and the 
calibrators passed the validation check recommended by the 
manufacturers of both the IgG and the IgM kits.
The descriptive data were given as means ± standard 
deviation (SD). The chi-squared test was used for the analytic 
assessment. The differences were considered to be statistically 
significant when the p-value obtained was <0.05.
Results
The response rate was 100%. There were 122 healthy donors; 
95.4%.were men, and 2 gender records were not completed. 
The mean age of respondents was 31.3±8.7 years overall, and 
33.2±9.0 for healthy male donors. A total of 122 donors were 
screened for anti-CMV IgG (Table I), of whom 96.7% were 
positive; 6.5% had a previous history of blood transfusion 
(Table II) and were all positive for anti-CMV IgG (100%). Of the 
114 (93.5%) without a history of blood transfusion, 110 (96.5%) 
were positive for anti- CMV IgG. No statistically significant 
association existed among healthy donors between history of 
blood transfusion and being anti-CMV IgG positive. Of the 121 
donors screened for anti- CMV IgM (Table I), only 19.5% were 
positive.
Interestingly, the 8 healthy donors who had been previously 
transfused were anti-CMV IgM negative (100%) (Table II) 
whereas 87 (76.9%) of the 114 without a history of transfusion 
were anti-CMV IgM negative. No significant association was 
established between anti-CMV IgM and history of blood 
transfusion among healthy blood donors.
Discussion
The 96% CMV IgG seroprevalence among blood donors in this 
study is in keeping with the study at Ibadan, Nigeria, with a 
seroprevalence of 100%.6 Similar seroprevalence rates of 90 - 
100% were also found in India.7-9 The high seroprevalence in 
Nigeria and India contrasts with Western literature, in which 
seroprevalence in blood donors ranges from 38% to 75%. A 
seroprevalence of 40% was found in highly industrialised 
nations.6
Table I. Anti-CMV IgG and anti-CMV IgM status among 
donors
    Anti-CMV IgG              Anti-CMV IgM
Status        screened   %           screened                %
Positive            118  96.7         26               19.5
Negative               4    3.3         95               80.5
   Total            122   100       121                100
Table II. History of blood transfusion and IgG/IgM status of blood donors
History of
transfusion Anti-CMV IgG positive Anti-CMV IgG negative Anti-CMV IgM positive Anti-CMV IgM negative
Positive       8   0     0     8
Negative   110   4   26   87
   Total   118   4   26   95
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We found an anti-CMV IgM seroprevalence of 19.5% among 
healthy blood donors, compared with 0% found in India.8 A 
decreased incidence of transfusion-associated CMV infection 
was found when only blood products negative for CMV IgM 
were used.10 Our finding of 19.5% CMV IgM seroprevalence in 
healthy blood donors predisposes 19.5% of preterm neonates 
to the risk of transfusion-associated CMV infection (TA-CMV) 
following exchanged blood transfusion in a country where 
screening for CMV is not routinely done. This is very likely, 
since most neonatal exchange transfusions require fresh blood 
rather than stored blood; the latter has a lesser risk of CMV 
transmission13 because CMV is transmitted by white blood cells 
which have a short lifespan (12 - 24 hours) both in vivo and in 
vitro.
There was no statistically significant association between 
history of blood transfusion and being CMV IgG/IgM positive 
among healthy donors. Hence, previous blood transfusion is 
not a risk factor for CMV antibody production as seen in this 
study, which is at variance with the finding of Tolpin et al.14 
However, studies on more than 1 500 blood donors have failed 
to confirm these observations.15
CMV infections are important clinical problems in patients 
with HIV infections and AIDS. The use of CMV-antibody-free 
blood component is indicated for CMV-antibody-negative 
AIDS patients.16
Conclusions
The seroprevalence of anti-CMV IgG and IgM is very high 
among blood donors in Nigeria. Based on previous studies 
that showed a decrease in the incidence of CMV disease when 
blood is screened for CMV (IgM), the incidence of the disease 
can be decreased in Lagos if blood is screened for CMV.
Limitations of this study
 Reliability of information on blood transfusion provided by 
patients and the possible reasons for finding small numbers of 
those who have been previously transfused.
 As most replacement donors in Lagos are males, because for 
cultural reasons many females are discouraged from blood 
donation, this may introduce significant gender bias to a 
seroprevalence study.
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